药品注册申请号:021083
申请类型:NDA (新药申请)
申请人:PF PRISM CV
申请人全名:PF PRISM CV
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 RAPAMUNE SIROLIMUS SOLUTION;ORAL 1MG/ML Yes Yes AA 1999/09/15 1999/09/15 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2022/08/22 SUPPL-70(补充) Approval Labeling STANDARD ;Orphan
2022/08/22 SUPPL-69(补充) Approval Labeling STANDARD ;Orphan
2020/01/02 SUPPL-67(补充) Approval Labeling STANDARD ;Orphan
2019/07/15 SUPPL-64(补充) Approval Labeling STANDARD ;Orphan
2019/06/18 SUPPL-66(补充) Approval Labeling STANDARD
2019/04/05 SUPPL-65(补充) Approval Labeling STANDARD ;Orphan
2018/05/23 SUPPL-61(补充) Approval Labeling STANDARD ;Orphan
2018/01/12 SUPPL-62(补充) Approval Labeling STANDARD ;Orphan
2017/04/11 SUPPL-59(补充) Approval Labeling STANDARD
2015/11/05 SUPPL-58(补充) Approval Labeling STANDARD ;Orphan
2015/07/31 SUPPL-57(补充) Approval Manufacturing (CMC) PRIORITY
2015/05/28 SUPPL-55(补充) Approval Efficacy PRIORITY ;Orphan
2015/03/06 SUPPL-56(补充) Approval Labeling STANDARD
2013/05/30 SUPPL-54(补充) Approval Labeling STANDARD
2013/03/07 SUPPL-53(补充) Approval Labeling STANDARD
2012/12/10 SUPPL-51(补充) Approval Labeling STANDARD
2011/07/11 SUPPL-49(补充) Approval Labeling UNKNOWN
2011/06/06 SUPPL-50(补充) Approval REMS N/A
2010/11/23 SUPPL-47(补充) Approval Labeling 901 REQUIRED
2010/11/23 SUPPL-44(补充) Approval Labeling UNKNOWN
2010/11/08 SUPPL-48(补充) Approval Labeling STANDARD
2010/07/02 SUPPL-46(补充) Approval Labeling UNKNOWN
2010/04/22 SUPPL-43(补充) Approval Labeling UNKNOWN
2010/04/22 SUPPL-42(补充) Approval Labeling UNKNOWN
2010/01/25 SUPPL-45(补充) Approval Labeling UNKNOWN
2009/10/08 SUPPL-41(补充) Approval Labeling 901 REQUIRED
2009/09/24 SUPPL-40(补充) Approval Labeling STANDARD
2009/01/29 SUPPL-38(补充) Approval Labeling STANDARD
2008/03/05 SUPPL-37(补充) Approval Labeling STANDARD
2008/03/05 SUPPL-36(补充) Approval Labeling STANDARD
2008/01/14 SUPPL-33(补充) Approval Efficacy STANDARD
2007/10/17 SUPPL-34(补充) Approval Labeling STANDARD
2007/05/02 SUPPL-31(补充) Approval Labeling STANDARD
2007/01/30 SUPPL-29(补充) Approval Efficacy UNKNOWN
2007/01/12 SUPPL-30(补充) Approval Labeling STANDARD
2007/01/09 SUPPL-26(补充) Approval Labeling STANDARD
2006/10/19 SUPPL-28(补充) Approval Labeling STANDARD
2006/06/02 SUPPL-25(补充) Approval Labeling STANDARD
2006/06/02 SUPPL-24(补充) Approval Efficacy UNKNOWN
2005/10/07 SUPPL-23(补充) Approval Labeling STANDARD
2005/10/07 SUPPL-22(补充) Approval Labeling STANDARD
2005/06/30 SUPPL-21(补充) Approval Labeling STANDARD
2005/06/30 SUPPL-20(补充) Approval Labeling STANDARD
2005/03/11 SUPPL-19(补充) Approval Efficacy PRIORITY
2004/07/20 SUPPL-17(补充) Approval Labeling STANDARD
2003/10/02 SUPPL-15(补充) Approval Labeling STANDARD
2003/04/11 SUPPL-6(补充) Approval Efficacy STANDARD
2003/03/19 SUPPL-14(补充) Approval Labeling STANDARD
2003/01/31 SUPPL-12(补充) Approval Labeling STANDARD
2003/01/23 SUPPL-10(补充) Approval Labeling STANDARD
2003/01/23 SUPPL-9(补充) Approval Labeling STANDARD
2003/01/23 SUPPL-8(补充) Approval Labeling STANDARD
2003/01/23 SUPPL-7(补充) Approval Labeling STANDARD
2003/01/23 SUPPL-5(补充) Approval Labeling STANDARD
2000/08/25 SUPPL-4(补充) Approval Labeling STANDARD
2000/05/03 SUPPL-2(补充) Approval Labeling STANDARD
2000/03/17 SUPPL-1(补充) Approval Manufacturing (CMC) PRIORITY ;Orphan
1999/09/15 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY ;Orphan
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 5100899 2013/07/07 U-290 PDF格式**本条是由Drugfuture回溯的历史信息**
5100899*PED 2014/01/07 PDF格式**本条是由Drugfuture回溯的历史信息**
5212155 2010/05/18 U-291 PDF格式**本条是由Drugfuture回溯的历史信息**
5212155*PED 2010/11/18 PDF格式**本条是由Drugfuture回溯的历史信息**
5308847 2011/05/03 U-292 PDF格式**本条是由Drugfuture回溯的历史信息**
5308847*PED 2011/11/03 PDF格式**本条是由Drugfuture回溯的历史信息**
5403833 2012/04/04 U-293 PDF格式**本条是由Drugfuture回溯的历史信息**
5403833*PED 2012/10/04 PDF格式**本条是由Drugfuture回溯的历史信息**
5536729 2013/09/30 Y PDF格式**本条是由Drugfuture回溯的历史信息**
5536729*PED 2014/03/30 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 D-114 2010/01/30**本条是由Drugfuture回溯的历史信息**
NPP 2008/03/11**本条是由Drugfuture回溯的历史信息**
ODE 2022/05/28**本条是由Drugfuture回溯的历史信息**
ODE-92 2022/05/28**本条是由Drugfuture回溯的历史信息**
PED 2006/10/11**本条是由Drugfuture回溯的历史信息**
PED 2008/09/11**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:SIROLIMUS 剂型/给药途径:SOLUTION;ORAL 规格:1MG/ML 治疗等效代码:AA
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021083 001 NDA RAPAMUNE SIROLIMUS SOLUTION;ORAL 1MG/ML Prescription Yes Yes AA 1999/09/15 PF PRISM CV
211040 001 ANDA SIROLIMUS SIROLIMUS SOLUTION;ORAL 1MG/ML Prescription No No AA 2019/01/28 NOVITIUM PHARMA
211212 001 ANDA SIROLIMUS SIROLIMUS SOLUTION;ORAL 1MG/ML Prescription No No AA 2019/10/18 AMNEAL
211406 001 ANDA SIROLIMUS SIROLIMUS SOLUTION;ORAL 1MG/ML Prescription No No AA 2019/10/22 APOTEX
215016 001 ANDA SIROLIMUS SIROLIMUS SOLUTION;ORAL 1MG/ML Discontinued No No AA 2021/12/27 TORRENT
216728 001 ANDA SIROLIMUS SIROLIMUS SOLUTION;ORAL 1MG/ML Prescription No No AA 2023/01/19 MSN
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database